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Abstract
Objective
To improve the genetic diagnosis of dominant optic atrophy (DOA), the most frequently
inherited optic nerve disease, and infer genotype-phenotype correlations.
Methods
Exonic sequences of 22 genes were screened by new-generation sequencing in patients with
DOA who were investigated for ophthalmology, neurology, and brain MRI.
Results
We identified 7 and 8 new heterozygous pathogenic variants in SPG7 and AFG3L2. Both genes
encode for mitochondrial matricial AAA (m-AAA) proteases, initially involved in recessive
hereditary spastic paraplegia type 7 (HSP7) and dominant spinocerebellar ataxia 28 (SCA28),
respectively. Notably, variants inAFG3L2 that result in DOA are located in different domains to
those reported in SCA28, which likely explains the lack of clinical overlap between these 2
phenotypic manifestations. In comparison, the SPG7 variants identified in DOA are in-
terspersed among those responsible for HSP7 in which optic neuropathy has previously been
reported.
Conclusions
Our results position SPG7 and AFG3L2 as candidate genes to be screened in DOA and indicate
that regulation of mitochondrial protein homeostasis and maturation by m-AAA proteases are
crucial for the maintenance of optic nerve physiology.
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Dominant optic atrophy (DOA, MIM*605290) is the most
commonly inherited optic neuropathy, leading to irreversible
loss of retinal ganglion cells (RGCs), optic nerve degeneration,
and central visual loss.1,2 More than 400 OPA1 variants were
identified in DOA individuals,3–6 resulting in excess of mito-
chondrial fission.7,8 Surprisingly, a similar clinical presentation
was also reported in individuals with dominant DNM1L
mutations9 (MIM603850) and mitochondrial network hyper-
fusion, thus providing evidence that alterations of both fusion
and fission compromise RGC survival. This hypothesis was
further supported by the identification in syndromic DOA
families of dominant mutations in MFN2 (MIM608507)10
and OPA3 (MIM606580),11 2 additional genes acting on mi-
tochondrial dynamics. More recently, a single SPG7
(MIM602783) mutation and a single AFG3L2 (MIM604581)
mutation were reported in DOA families,12–14 although
mutations in these genes are commonly known to be re-
sponsible for the recessive hereditary spastic paraplegia type 7
(HSP7)15 and dominant spinocerebellar ataxia 28 (SCA28),16
respectively. In addition, the occurrence of heterozygous var-
iants in SPG7 and AFG3L2 was identified in a patient affected
with DOA and parkinsonism,17 a clinical presentation found in
few patients with OPA1.18 SPG7 and AFG3L2 are paralogue
genes encoding mitochondrial matricial AAA (m-AAA)-
proteases involved in protein homeostasis and the cleavage of
the OMA1 and YME1L mitochondrial proteases, which con-
trol the shift between profusion long and profission short
OPA1 isoforms.19
This prompted us to screen SPG7 and AFG3L2 exonic
sequences in patients with DOA without molecular diagnosis.
We report the identification of pathogenic variants in these 2
genes in nonsyndromic patients with DOA.
Methods
Standard protocol approvals, registrations,
and patient consents
Written informed consent to perform genetic analyses was
obtained from each subject involved in this study or from the
parents of individuals younger than 18 years of age, according to
the protocols approved by the ethical committees of the dif-
ferent institutes involved in this study and in agreement with the
Declaration of Helsinki (Institutional Review Board Committee
of the University Hospital of Angers, Authorization number:
AC-2012-1507).
Genetic analysis
Genomic DNA was extracted from peripheral blood cells
from multinational cohorts of DOA and sporadic cases of
optic atrophy, initially screened for OPA1, OPA3, andWFS1
exonic sequences and the 3 primary Leber hereditary optic
neuropathy mutations. Cases negative after this primary
screening were analyzed by resequencing a panel of 22 genes
(table e-1, links.lww.com/NXG/A260) involved in inherited
optic neuropathies or in mitochondrial dynamics. Library
preparation for each sample was performed using an Ion
AmpliSeq Library Kit 2.0 (Cat. no. 4480441) according to
the manufacturer’s protocol (Thermo Fisher Scientific,
MAN0006735). Sample emulsion PCR, emulsion breaking,
and enrichment were performed using the Ion 540 Kit–Chef
(Cat. no. A27759) according to the manufacturer’s
instructions (Thermo Fisher Scientific, MAN0010851).
Sequencing was performed using a 540 ChIPs on an Ion S5
Sequencer using the barcoded samples. Sequencing data
were processed using our own dedicated bioinformatics
pipeline, as described elsewhere.20 Candidate pathogenic
variants were validated by Sanger sequencing, and their
segregation was assessed in DNAs from other members of
the families, when available.
Cell studies
Fibroblasts fromAFG3L2 individuals P1: III:2 and P2: II:1 from
family 9 and 15, respectively, were generated from skin biopsies
and cultured in 2/3 Dulbecco’s Minimum Essential Medium
(DMEM,Gibco) supplementedwith 1/3 AmnioMAX (Gibco),
10% fetal calf serum (Lonza), and 1% Penicillin-Streptomycin-
Amphotericin B (Lonza). Mitochondrial network analysis, re-
spiratory chain enzymatic activities, and mtDNA copy number
were assessed as described.9
Data availability
All data relevant to this study are contained within the article.
Results
Identification of SPG7 and AFG3L2 pathogenic
variants in individuals with DOA or isolated
optic atrophy using a targeted
sequencing panel
Six hundred cases without positive result after screening
OPA1, OPA3, andWFS1 exonic sequences and the 3 primary
Leber hereditary optic neuropathy mutations were included
in a resequencing program focused on 22 genes, among
which were those already firmly established for DOA and
recessive optic atrophy and candidate genes encoding actors
of the mitochondrial dynamics. After eliminating frequent
(>1/10.000) and nonpathogenic variants, according to the
SIFT, PolyPhen, MutationTaster, and LRT prediction tools,
we identified 7 and 8 individuals harboring a SPG7 or an
Glossary
DOA = dominant optic atrophy; HSP7 = hereditary spastic paraplegia; OCT = optical coherence tomography; RGC = retinal
ganglion cell; RNFL = retinal nerve fiber layer; SCA28 = spinocerebellar ataxia.
2 Neurology: Genetics | Volume 6, Number 3 | June 2020 Neurology.org/NG
AFG3L2 pathogenic heterozygous variant, respectively.
These variants were confirmed by Sanger sequencing and
analyzed for segregation whenever possible in the respective
families. Segregation of the 15 variants fitted with the clinical
features of affected individuals for whom DNA samples were
available (Figure 1). In family 13, the c.1126G > A variant in
AFG3L2 was not found in both parents, suggesting that it
occurred de novo.
Phenotypic manifestations of SPG7 and AFG3L2
mutation carriers
All individuals included were referred to ophthalmology
departments for visual acuity impairment. At inclusion, none of
them complained of spastic paraplegia or SCA, and in all cases
but one, the brain MRI was normal. All patients with SPG7
presented optic disk pallor and accordingly, reduced retinal
nerve fiber layer (RNFL) at optical coherence tomography
(OCT) scanning, mainly on the temporal side (figure 2A).
Nevertheless, their visual acuity alterations were mild, with
scores ranging from 3/10 to 10/10 (table 1) and occurring
during midlife for all individuals except one (family 3, II-1).
Patient II.1 from family 4 with the best visual acuity only pre-
sented a significant reduction of the RNFL at the OCT exam-
ination. No additional symptom was observed for the index
cases and their relatives when the clinical data were available,
except for a hearing impairment in family 5 (table 1).
Conversely, all AFG3L2mutated individuals disclosed a severe
optic atrophy with visual acuities ranging from 0.2/10 to 2/10,
except for the 3 members of family 7 who had visual acuity
scores above 4/10 (table 1). First ophthalmologic examination
occurred in a broad range of age, with some individuals being
affected early during the first 2 decades, as reported for patients
withOPA1.1 All patients disclosed optic nerve pallor and highly
reduced RNFL at OCT scanning (figure 2B). Similar to SPG7,
no brain MRI abnormality was reported in investigated
patients, except for patient II.1 from family 14, who had a pi-
tuitary adenoma without cerebellar atrophy. This individual
had a hearing impairment in addition to a very low visual acuity
(table 1).
Functional consequences of SPG7 and
AFG3L2mutations
SPG7 and AFG3L2 encode highly similar proteins with 5
conserved domains (figure 3). Four of the DOA mutations in
SPG7 are referenced with a frequency close to 1e-05 in the
GnomAD database, whereas the 3 others were not referenced.
All SPG7 variants responsible for DOA are interspersed with
the recessive variants responsible for HSP7, and 2 of them are
deletions leading to a frameshift at positions 258 and 654.
These latter data suggest that SPG7 haploinsufficiency might
be the primary causal pathologic process in DOA. Surprisingly,
other heterozygote composite frameshift mutations were
Figure 1 SPG7 and AFG3L2 pedigrees
Description of the pedigreeswith SPG7 (top) and AFG3L2 (middle and bottom)mutations and their segregation among theDOA families. DOA=dominant optic
atrophy.
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reported to cause HSP7, even at an earlier position toward the
N-end of the protein (figure 3A). Unfortunately, no individual
with a SPG7 variant accepted to provide a skin biopsy to infer
fibroblasts for functional validation.
Seven out of the 8 AFG3L2 variants identified in this study
were not referenced in any database. They result in missense
amino acid changes (table 1), and all but one (p.Thr644Ser
from family 14) are located in domains different from the
one involved in SCA28 individuals, suggesting that they af-
fect another AFG3L2 function than the one responsible for
the SCA28 phenotype (figure 3B). Two fibroblast cell lines
were established from individuals III:2 from family 9 and II:1
from family 15 to assess their mitochondrial shape and
physiology. A tendency toward mitochondrial fragmentation
was observed in AFG3L2 fibroblasts (figure e-1, links.lww.
com/NXG/A261), together with a significant reduction of
CI, CIII, and CIV enzymatic activities, which correlated with
a significant citrate synthase decreased activity, suggesting
a reduction of the mitochondrial mass. This prompted the
analysis of mitochondrial DNA copy number (figure e-1),
which showed a significant 50% reduction in AFG3L2 cells.
Figure 2 Ophthalmologic exploration of SPG7 and an AFG3L2 affected individuals
Left: Eye fundus pictures of individuals with SPG7 (A, family 5, II.1 and family 6 II.1) and individuals with AFG3L2 (B, family 9, III:2 and family 12, II.1) revealing the
temporal pallor of the optic discs in both REs and LEs. Right: RNFL by optic coherence tomography in individuals, disclosing the mild reduction of RNFL
thickness in the individualswith SPG7 (A) and the severe one in the individualswith AFG3L2 (B). The green area defines the 5th to 95th, the yellowarea the 1st to
5th, and the red area below the 1st percentiles. INF = inferior quadrants; LE = left eye; NAS = nasal; RE = right eye; RNFL = retinal nerve fiber layer assessment;
SUP = superior; TEMP = temporal.
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Discussion
Dominant SPG7 and AFG3L2 mutations can result in isolat-
ed optic nerve involvement with a clinical phenotype
indistinguishable from that seen in patients with DOA harbor-
ing dominant OPA1 mutations. As in OPA1-positive DOA,
SPG7 and AFG3L2 mutation carriers can present with a broad
spectrum of visual impairment ranging from asymptomatic
Table 1 Clinical data of the patients with SPG7 and AFG3L2
Family Patient Sex Age VA
Other
symptoms Brain MRI Gene
ORF
mutation Protein change rs #
GnomAD
Freq.
1 I.1 F 42 4/10 — Normal SPG7 c.1960_
1963delGTCA
p.Val654Profs*7 Unknown
2 II.1 M 43 3/10 Liver
cirrhosis
ND SPG7 c.773-
774delTG
p.Val258Glyfs*30 rs768136171 8.03e-06
3 II.1 F 8 5/10 — Normal SPG7 c.934G>C p.Ala312Pro Unknown
4 II.1 F 66 10/
10
— Normal SPG7 c.392G>A p.Arg131His rs985921704 7.99e-06
5 II.1 F 31 9/10 Hearing
impairment
ND SPG7 c.1048C>T p.Pro350Ser rs199789849 2 e-05
6 II.1 F 64 5/10 — Normal SPG7 c.209C>A p.Pro70His Unknown
7 II.1 F 62 2&9/
10
— Normal SPG7 c.2191G>A p.Ala731Thr rs747521455 3.19e-5
8 III.2 M 36 5/10 — Normal AFG3L2 c.1248A>T p.Arg416Ser Unknown
IV.1 M 7 5/10 — Normal AFG3L2 c.1248A>T p.Arg416Ser
IV.4 M 8 4/10 — Normal AFG3L2 c.1248A>T p.Arg416Ser
9 II.2 F 47 2/10 — Normal AFG3L2 c.1541C>T p.Pro514Leu Unknown
III.1 F 26 1/10 — Normal AFG3L2 c.1541C>T p.Pro514Leu
III.2 M 22 1/10 — Normal AFG3L2 c.1541C>T p.Pro514Leu
III.3 F 15 1/10 — Normal AFG3L2 c.1541C>T p.Pro514Leu
10 I.2 M 80 1/10 — ND AFG3L2 c. 1010 G>A p.Gly337Glu Unknown
II.1 M 61 1.6/
10
— ND AFG3L2 c. 1010 G>A p.Gly337Glu
II.2 M 60 1.6/
10
— ND AFG3L2 c. 1010 G>A p.Gly337Glu
II.3 M 58 1.6/
10
— ND AFG3L2 c. 1010 G>A p.Gly337Glu
11 I.1 F 46 0.5/
10
— Normal AFG3L2 c.1009G>A p.Gly337Arg Unknown
II.1 F 13 0.5/
10
— Normal AFG3L2 c.1009G>A p.Gly337Arg
II.2 M 7 0.8/
10
— Normal AFG3L2 c.1009G>A p.Gly337Arg
12 II.1 F 25 0.2/
10
— Normal AFG3L2 c.1541C>T p.Pro514Leu Unknown
13 II.1 F 9 1.3/
10
— Normal AFG3L2 c.1126G>A p.Glu376Lys Unknown
14 II.1 M 59 1.6/
10
— Normal AFG3L2 c.1931C>G p.Thr644Ser rs1226952405 3.98e-06
15 II.1 F 19 0.5/
10
Hearing
impairment
Pituitary
adenomas
AFG3L2 c.221A>C p.Glu74Ala Unknown
Abbreviations: GnomAD Freq. = frequency in the genome aggregation database; ND = not done; ORF = open reading frame; rs # = reference sequence
number; VA = visual acuity.
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mutation carriers to legal blindness and, in some of them, to
a more severe syndromic manifestation with sensorineural
deafness.21
It is intriguing that SPG7mutations can behave both dominantly
and recessively with variable tissue specificity. Of interest, in
a previous work reporting novel SPG7 mutations, 10 affected
individuals underwent an ophthalmologic examination and all of
themhad evidence of amild optic neuropathywith bilateral optic
disc pallor and thinning of the peripapillary RNFL on OCT
imaging.12 Conversely, the neurologic examination by the same
team of the first-identified SPG7-related DOA family did not
evidence any gait or walking difficulties in mutation carriers. In
addition, the SPG7 variants that we identified in individuals with
DOA are interspersed with the recessive variants resulting in
HSP7, and in both diseases frameshift variants are contributing
to the pathophysiologic mechanism. Altogether, these data
suggest a clinical overlap related to SPG7 mutations between
DOA on one end and HSP7 on the other end and all possible
mixed phenotype inbetween. These observations should prompt
to perform a systematic neuroophthalmological examination of
individuals with HSP7 and their heterozygous parents. Similarly,
DOA individuals with a SPG7 variant should have a neurologic
follow-up, particularly older than the age of 40 years, to evaluate
the eventual occurrence of spasticity and also cognitive impair-
ment, epilepsy, and cerebellar atrophy.
Dominant mutations in AFG3L2 were initially found in
individuals affected with SCA28 and do localize in exons 15
and 16, in addition to one in exon 10.22 Recessive consan-
guineous AFG3L2 mutations in exon 15 were also identified
in a spastic ataxia-neuropathy syndrome23 (SPAX5),
whereas 2 additional dominant AFG3L2 variants were
identified in an individual affected with myoclonus and py-
ramidal signs24 and a recessive mutation in another family
affected with microcephaly, early onset seizures, spasticity,
and basal ganglia atrophy.25 Of interest, the 8 missense
AFG3L2 variants that we identified in individuals with DOA
are involving other domains than those identified earlier,
thus explaining the absence of clinical overlap between all
the symptoms previously described for AFG3L2 mutations
and the optic atrophy found in this study. This is reinforced
by the normality of the brain MRI and the absence of ataxia
in AFG3L2-related patients with DOA. Nevertheless, we
suggest that the ophthalmologic follow-up of these individ-
uals should be accompanied by a neurologic examination to
eventually diagnose early manifestations of cerebellar ataxia
or any other clinical symptoms.
The 2 m-AAA proteases encoded by SPG7 and AFG3L2
genes have been described as promoting OPA1 cleavage to
its short profission isoforms.19 This activity is under the
control of OMA1 and YME1L proteases that directly process
Figure 3 Structural representation of SPG7 and AFG3L2 amino acid changes related to mutations in individuals with DOA,
HSP7, and SCA28/SPAX5
(A): Structure and domains of the SPG7 protein with the amino acid changes associated with DOA (top) and HSP7 (bottom); red, mutations identified in this
study; purple, a DOA mutation previously reported; and black: HSP7 published mutations. (B): Structure and domains of the AFG3L2 protein with the amino
acid changes associated with DOA (top) and to other diseases (bottom); red, mutations identified in this study; purple, a previously reported DOAmutation;
black, published mutations responsible for SCA28; blue, published mutations responsible for recessive spastic ataxia SPAX5; in green, myoclonus and
pyramidal signs; and in orange, microcephaly, early onset seizures, spasticity, and basal ganglia atrophy. DOA = dominant optic atrophy; SCA28 = spino-
cerebellar ataxia; SPAX5 = spastic ataxia-neuropathy syndrome.
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the cleavage of OPA1.26 Our data suggest that this mecha-
nism might be affected by the dominant variants in both
genes, although at different levels, depending on the mutated
gene. Indeed, AFG3L2 forms both homopolymers and
heteropolymers with SPG7; therefore, pathogenic variants
should affect the activity of both types of polymers. Con-
versely, SPG7 can only form heteropolymers with AFG3L2,
but not homopolymers, implying that pathogenic variants
should only affect the activity of the AFG3L2-SPG7 heter-
opolymers. This might explain the relatively mild visual
deficits in individuals with SPG7 variants, contrasting with
the more severe visual loss observed in individuals with
AFG3L2 variants and the syndromic DOA plus phenotype
found in a patient harboring concurrent mutations in both
genes. It further questions the possible specificity of these
mutations for the regulation of OPA1 processing. In this
respect, mitochondrial dynamic might be affected by the
other SPG7mutations but overwhelmed by the severe HSP7
phenotype, whereas it is apparently not affected by the
AFG3L2 variants involved in SCA28. This reflect the fact
that no optic atrophy has been yet reported in the mouse
models harboring Spg7 or Afg3l2 mutations.
Thus, we provide compelling evidence that heterozygous
SPG7 and AFG3L2 mutations should be considered in the
cases of isolated DOA, more so when already found to be
OPA1-negative. Our findings stress the central role mediated
by m-AAA proteases in the regulation of mitochondrial dy-
namics and how dysfunction of these pathways compro-
mise the RGC integrity and survival, resulting in optic
neuropathy.
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